Stockscreener 앱 받기
151.66
0.15%
-0.34
전일 마감가:
$152.00
열려 있는:
$151.43
하루 거래량:
79,482
Relative Volume:
0.21
시가총액:
$9.62B
수익:
$3.57B
순이익/손실:
$335.95M
주가수익비율:
30.45
EPS:
4.98
순현금흐름:
$377.60M
1주 성능:
+1.38%
1개월 성능:
+8.27%
6개월 성능:
-10.89%
1년 성능:
+3.38%
1일 변동 폭
$151.43
$153.22
1주일 범위
$146.96
$153.22
52주 변동 폭
$130.85
$178.03
Aptargroup Inc Stock (ATR) Company Profile
명칭
Aptargroup Inc
전화
(815) 477-0424
주소
265 EXCHANGE DRIVE, CRYSTAL LAKE, IL
ATR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATR
Aptargroup Inc
|
151.79 | 9.62B | 3.57B | 335.95M | 377.60M | 4.98 |
|
ISRG
Intuitive Surgical Inc
|
535.18 | 184.23B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
168.94 | 48.46B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
98.15 | 47.15B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
241.22 | 35.24B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.09 | 16.39B | 3.90B | 392.30M | 288.10M | 1.95 |
Aptargroup Inc Stock (ATR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-07 | 개시 | Raymond James | Outperform |
| 2025-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-14 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-01-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-08-02 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-04-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-14 | 개시 | Seaport Global Securities | Neutral |
| 2020-04-27 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-03-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-03-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-02-26 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-07-08 | 개시 | Morgan Stanley | Overweight |
| 2019-04-05 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-05-18 | 개시 | Jefferies | Hold |
| 2016-12-07 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2016-10-13 | 개시 | Jefferies | Hold |
| 2016-01-05 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2015-11-02 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2015-09-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-05-01 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2013-02-19 | 재확인 | Deutsche Bank | Hold |
| 2013-01-08 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2012-07-10 | 다운그레이드 | KeyBanc Capital Mkts | Buy → Hold |
| 2012-04-11 | 개시 | KeyBanc Capital Mkts | Buy |
| 2011-06-13 | 업그레이드 | KeyBanc Capital Mkts | Hold → Buy |
모두보기
Aptargroup Inc 주식(ATR)의 최신 뉴스
Aptar CSP Launches cGMP-Compliant Manufacturing Facility in NJ - Contract Pharma
Aptar Reports Second Quarter 2024 Results - Seeking Alpha
AptarGroup, Inc. (NYSE:ATR) Q1 2025 Earnings Call Transcript - Insider Monkey
AptarGroup Inc (ATR) Q1 2025 Earnings Call Highlights: Navigating Currency Headwinds and Tax ... - Yahoo
AptarGroup Inc (ATR) Q1 2025 Earnings Call Highlights: Navigating Currency Headwinds and Tax ... By GuruFocus - Investing.com Canada
AptarGroup’s Q1 2025 Results: Sales Dip, Pharma Grows - TipRanks
Earnings call transcript: AptarGroup Q1 2025 sees modest EPS beat By Investing.com - Investing.com South Africa
AptarGroup’s Earnings Call: Growth Amid Challenges - TipRanks
Aptar (ATR) Reports Q1 Revenue Miss but Highlights Strong Segmen - GuruFocus
Earnings call transcript: AptarGroup Q1 2025 sees modest EPS beat - Investing.com
APTARGROUP, INC. SEC 10-Q Report - TradingView
AptarGroup (ATR) Surpasses Q1 EPS Expectations, Provides Optimis - GuruFocus
AptarGroup: Q1 Earnings Snapshot - MySA
Aptar Q1 2025 slides: Flat sales but improved margins amid segment variability By Investing.com - Investing.com South Africa
AptarGroup Inc (ATR) Q1 2025 Earnings: EPS of $1.17 Beats Estima - GuruFocus
Aptar (ATR) Positioned for Strong Performance with Resilient Mar - GuruFocus
Aptargroup Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptar Reports First Quarter 2025 Results | ATR Stock News - GuruFocus
Aptar Q1 2025 slides: Flat sales but improved margins amid segment variability - Investing.com India
AptarGroup (ATR) Q1 Earnings Top Estimates - Yahoo Finance
Aptar Reports First Quarter 2025 Results - Aptar
AptarGroup Q1 Earnings, Revenue Fall - marketscreener.com
AptarGroup, Inc. Reports First Quarter 2025 Results - TradingView
Earnings Flash (ATR) APTARGROUP INC. Reports Q1 Adjusted EPS $1.20, vs. FactSet Est of $1.16 - marketscreener.com
AptarGroup Inc (ATR) Q1 2025 Earnings Report Preview: What to Lo - GuruFocus
Subdued Growth No Barrier To AptarGroup, Inc.'s (NYSE:ATR) Price - simplywall.st
Aptar Named One of America’s Climate Leaders by USA Today for Third Consecutive Year - Aptar
AptarGroup About To Put More Money In Your Pocket (ATR) - Nasdaq
Aptar Pharma Presents Webinar on GLP-1 Drug Development - Aptar
Aptar Reports Fourth Quarter and Annual 2024 Results - ADVFN
AptarGroup (ATR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo
Here’s Why Upslope Capital Management Exited its Stake in AptarGroup (ATR) - MSN
AptarGroup (ATR) Price Target Lowered by Raymond James Amid Cautious Outlook | ATR Stock News - GuruFocus
Aptar Declares Quarterly Dividend - BioSpace
AptarGroup Keeps Quarterly Dividend at $0.45 a Share, Payable May 22 to Holders of Record on May 1 - marketscreener.com
Aptar Declares Quarterly Dividend – April 2025 - Aptar
Aptar Declares Quarterly Dividend | ATR Stock News - GuruFocus
AptarGroup Sets $0.45 Quarterly Dividend: What the May Earnings Call Could Reveal - Stock Titan
Will AptarGroup (ATR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Is AptarGroup, Inc.'s (NYSE:ATR) Recent Stock Performance Tethered To Its Strong Fundamentals? - simplywall.st
AptarGroup Launching Validation Study of SmartTrack Platform - marketscreener.com
AptarGroup (ATR) Launches Clinical Study for SmartTrack Platform Validation | ATR Stock News - GuruFocus
Aptar Receives Platinum Rating from EcoVadis for the Fifth Conse - GuruFocus
AptarGroup begins study for generic drug approval process - Investing.com Australia
AptarGroup begins study for generic drug approval process By Investing.com - Investing.com Canada
Aptar Announces Clinical Validation Study to Accelerate US FDA Approval of SmartTrack™ In-Vitro-in-Silico Platform for Pressurized Metered-Dose Inhalers - marketscreener.com
Aptar Receives Platinum Rating from EcoVadis for the Fifth Consecutive Year - GuruFocus
Aptargroup Inc (ATR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
0.32%
자본화:
|
볼륨(24시간):